Synchron Stentrode: Primary Endpoint Met in Feasibility Trial

• Source: https://www.clinicaltrialsarena.com/news/synchrons-bci-meets-primary-endpoint-in-feasibility-trial/
• Type: technical-report
• Institution: Synchron
• Date Ingested: 2026-04-05T20:00:00Z
• Tags: synchron, stentrode, clinical-trial, fda, minimally-invasive

Key Contribution

12-month safety and efficacy data from 6 patients. First FDA-approved permanently implanted BCI to meet primary endpoints. $200M Series D funding secured for pivotal trials in 2026.

Summary

Synchron's Stentrode brain-computer interface has met its primary endpoint in a feasibility trial, demonstrating both safety and efficacy over 12 months in 6 patients. This makes Synchron the first company to achieve this milestone with an FDA-approved permanently implanted BCI.

Stentrode Technology

• Minimally invasive: Implanted via blood vessels (jugular vein) — no open brain surgery required
• Stent-electrode array: Small wire mesh device deployed in the superior sagittal sinus adjacent to motor cortex
• Signal acquisition: Records neural activity through blood vessel walls
• Permanent implant: Designed for long-term, chronic use

Trial Results

• Patients: 6 participants with severe paralysis
• Duration: 12-month follow-up data
• Primary endpoint: Met — demonstrating acceptable safety profile and meaningful efficacy
• Safety: No serious adverse events related to the device
• Efficacy: Patients able to control digital devices using neural signals

Commercialization Path

• Funding: $200M Series D — significant capital for medical device development
• Pivotal trials: Planned for 2026 — larger patient population, controlled study design
• FDA pathway: Building on IDE (Investigational Device Exemption) approval
• Market entry: Potentially 2028-2029 if pivotal trials succeed

Competitive Advantage

• No brain surgery — dramatically lower risk than cortical implants (Neuralink, Blackrock)
• Faster recovery, lower infection risk, broader patient eligibility
• Proven long-term stability (12+ months without repositioning)
• Trade-off: lower signal resolution than intracortical arrays

Significance

Synchron's feasibility trial success is a milestone for the BCI field. The minimally invasive approach via blood vessels could make BCIs accessible to a much larger patient population than intracortical implants requiring craniotomy. Meeting the primary endpoint with 12-month data provides the evidence base needed for pivotal trials. The $200M raise demonstrates investor confidence. If pivotal trials confirm these results, Stentrode could become the first commercially available BCI — potentially beating Neuralink to market despite Neuralink's higher-profile program.